Epicatechin

Pharmacology & Research

(−)-Epicatechin is the flavan-3-ol most credited as the “active” behind the cocoa-flavanol cardiovascular story — and it is a cautionary tale about the isolate-vs-mixture gap. Almost every positive human trial dosed a cocoa-flavanol mixture (or dark chocolate), in which epicatechin travels with (+)-catechin, procyanidins, theobromine and other flavanols; when investigators isolate pure (−)-epicatechin and test it against placebo, the vascular signal largely disappears ^{4,5Reference 4Dower JI et al. · 2015RCTEffects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health — a randomised, double-blind, placebo-controlled crossover trialView study →Reference 52018RCTA nutritive dose of pure (−)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults — a randomised, placebo-controlled, double-blind crossover studyView study →}. So the honest picture is: strong evidence for the cocoa/flavan-3-ol class, weak-to-null evidence for the purified monomer. Keep it distinct throughout from (+)-catechin (its epimer), EGCG (the gallated green-tea catechin) and the proanthocyanidin polymers it helps build. Unusually for a flavonoid, (−)-epicatechin is well absorbed (~82% of a dose) — but it still circulates as conjugates and microbial metabolites, not the free aglycone ^{16Reference 16Ottaviani JI et al. · 2016The metabolome of 2-¹⁴C-epicatechin in humans — implications for the assessment of efficacy, safety and mechanisms of action of polyphenolic bioactivesView study →}.

1. Endothelial function & blood pressure

The strongest area — for the class. Meta-analyses of cocoa-flavanol RCTs show improved flow-mediated dilation (chronic +1.34%, acute +3.19%) and small falls in blood pressure (diastolic/mean ≈ −1.6 mmHg) ^{1,2Reference 1González-Sarrías A et al. · 2016Meta-analysisCocoa flavanol intake and biomarkers for cardiometabolic health — a systematic review and meta-analysisView study →Reference 22025Meta-analysisImpact of flavan-3-ols on blood pressure and endothelial function in diverse populations — a systematic review and meta-analysis of randomised controlled trialsView study →}, with a cocoa dose-response model for BP ^{3Reference 3Ellinger S et al. · 2012Epicatechin ingested via cocoa products reduces blood pressure in humans — a nonlinear regression model with a Bayesian approachView study →} and a dietary-bioactive guideline rating the class evidence “moderate” at 400–600 mg/day flavan-3-ols ^{9Reference 9Crowe-White KM et al. · 2022Flavan-3-ols and cardiometabolic health — first ever dietary bioactive guidelineView study →}.

Gap: the tested agent is almost always a cocoa-flavanol mixture, not epicatechin. When pure (−)-epicatechin was given at a pharmacological 100 mg/day it did not improve FMD or blood pressure ^{4Reference 4Dower JI et al. · 2015RCTEffects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health — a randomised, double-blind, placebo-controlled crossover trialView study →}, and a 25 mg/day “nutritive dose” was likewise null ^{5Reference 52018RCTA nutritive dose of pure (−)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults — a randomised, placebo-controlled, double-blind crossover studyView study →}. The class effect is real; transferring it to the isolated monomer is not supported.

2. Cardiovascular events & mortality

The one hard-outcome test. COSMOS (n=21,442) gave a cocoa-flavanol extract (500 mg flavanols including ~80 mg epicatechin); the primary total-cardiovascular endpoint was not significant (HR 0.90, 95% CI 0.78–1.02), though a secondary cardiovascular-death reduction (~27%) appeared, stronger in adherent participants ^{6Reference 6Sesso HD et al. · 2022RCTEffect of cocoa flavanol supplementation for the prevention of cardiovascular disease events — the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomised clinical trialView study →}. Observational data are split: dietary epicatechin tracked lower cardiovascular mortality in one elderly cohort ^{7Reference 7Dower JI et al. · 2016Dietary epicatechin intake and 25-y risk of cardiovascular mortality — the Zutphen Elderly StudyView study →}, while EPIC-Norfolk found no consistent flavan-3-ol/CVD association ^{8Reference 8Vogiatzoglou A et al. · 2015ObservationalAssociations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk)View study →}.

Gap: COSMOS used a cocoa extract, its primary endpoint was null, and the CV-death signal is a secondary finding requiring confirmation; the cohorts are observational and inconsistent. This is suggestive, not established ^{6,8Reference 6Sesso HD et al. · 2022RCTEffect of cocoa flavanol supplementation for the prevention of cardiovascular disease events — the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomised clinical trialView study →Reference 8Vogiatzoglou A et al. · 2015ObservationalAssociations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk)View study →}.

3. Muscle & mitochondrial function

The one place isolated epicatechin leads the evidence. A small RCT combined resistance training with epicatechin in sarcopenic older adults and reported improved strength and a higher follistatin/myostatin ratio ^{10Reference 10Mafi F et al. · 2019Improvement in skeletal muscle strength and plasma levels of follistatin and myostatin induced by an 8-week resistance training and epicatechin supplementation in sarcopenic older adultsView study →}, and an open-label pilot in Becker muscular dystrophy raised PGC-1α and mitochondrial markers ^{11Reference 11McDonald CM et al. · 2021McDonald CM, Ramirez-Sanchez I, Oskarsson B, et al. (2021). (−)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy. Muscle & Nerve, 63(2), 239–249. https://pubmed.ncbi.nlm.nih.gov/33125736/View study →}.

Gap: small, preliminary, partly open-label — and a genuine caution: a controlled cycling RCT found epicatechin blunted aerobic training adaptation (lower VO₂ gains) ^{12Reference 12Schwarz NA et al. · 2018Schwarz NA, Blahnik ZJ, Prahadeeswaran S, et al. (2018). (−)-Epicatechin supplementation inhibits aerobic adaptations to cycling exercise in humans. Frontiers in Nutrition, 5, 132. https://pubmed.ncbi.nlm.nih.gov/30622947/View study →}. So the mitochondrial story is intriguing but two-edged, and far from established ^{10,12Reference 10Mafi F et al. · 2019Improvement in skeletal muscle strength and plasma levels of follistatin and myostatin induced by an 8-week resistance training and epicatechin supplementation in sarcopenic older adultsView study →Reference 12Schwarz NA et al. · 2018Schwarz NA, Blahnik ZJ, Prahadeeswaran S, et al. (2018). (−)-Epicatechin supplementation inhibits aerobic adaptations to cycling exercise in humans. Frontiers in Nutrition, 5, 132. https://pubmed.ncbi.nlm.nih.gov/30622947/View study →}.

4. Metabolic & cognitive markers

Weak. Cocoa-flavanol meta-analyses show small shifts in insulin/HOMA-IR ^{1Reference 1González-Sarrías A et al. · 2016Meta-analysisCocoa flavanol intake and biomarkers for cardiometabolic health — a systematic review and meta-analysisView study →}, but pure (−)-epicatechin did not improve cardiometabolic risk factors in overweight/metabolic-syndrome adults ^{5Reference 52018RCTA nutritive dose of pure (−)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults — a randomised, placebo-controlled, double-blind crossover studyView study →}. For cognition, the COSMOS-Mind RCT found a cocoa extract gave no overall benefit over three years (the trial’s multivitamin arm did) ^{13Reference 13Baker LD et al. · 2023RCTEffects of cocoa extract and a multivitamin on cognitive function — a randomised clinical trial (COSMOS-Mind)View study →}.

Gap: metabolic effects are small, mixture-based and inconsistent; the best cognition RCT is null. No support for the isolated monomer here ^{5,13Reference 52018RCTA nutritive dose of pure (−)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults — a randomised, placebo-controlled, double-blind crossover studyView study →Reference 13Baker LD et al. · 2023RCTEffects of cocoa extract and a multivitamin on cognitive function — a randomised clinical trial (COSMOS-Mind)View study →}.

Mechanisms

Target / pathway	Effect	Relevant to	Evidence
eNOS activation → nitric oxide (post-translational, PI3K/Akt)	vasodilation, ↑ arterial compliance	endothelial function, BP	in-vitro human endothelial cells 14,15Reference 14Ramirez-Sanchez I et al. · 2010Ramirez-Sanchez I, Maya L, Ceballos G, Villarreal F. (2010). (−)-Epicatechin activation of endothelial cell endothelial nitric oxide synthase, nitric oxide, and related signaling pathways. Hypertension, 55(6), 1398–1405. https://pubmed.ncbi.nlm.nih.gov/20404222/View study →Reference 15Ramirez-Sanchez I et al. · 2011Ramirez-Sanchez I, Maya L, Ceballos G, Villarreal F. (2011). (−)-Epicatechin induces calcium and translocation-independent eNOS activation and increases NO in human endothelial cells. European Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/21327831/View study →
NO-mediated vasodilation → ↑ cGMP	small DBP/MAP fall	blood pressure	cocoa RCT meta-analyses 1,2Reference 1González-Sarrías A et al. · 2016Meta-analysisCocoa flavanol intake and biomarkers for cardiometabolic health — a systematic review and meta-analysisView study →Reference 22025Meta-analysisImpact of flavan-3-ols on blood pressure and endothelial function in diverse populations — a systematic review and meta-analysis of randomised controlled trialsView study →
Mitochondrial biogenesis (↑ PGC-1α, AMPK)	more/denser mitochondria	muscle, metabolic	pilot + small RCT 10,11Reference 10Mafi F et al. · 2019Improvement in skeletal muscle strength and plasma levels of follistatin and myostatin induced by an 8-week resistance training and epicatechin supplementation in sarcopenic older adultsView study →Reference 11McDonald CM et al. · 2021McDonald CM, Ramirez-Sanchez I, Oskarsson B, et al. (2021). (−)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy. Muscle & Nerve, 63(2), 239–249. https://pubmed.ncbi.nlm.nih.gov/33125736/View study →
Myokine modulation (↑ follistatin, ↓ myostatin)	strength	muscle	small RCT 10Reference 10Mafi F et al. · 2019Improvement in skeletal muscle strength and plasma levels of follistatin and myostatin induced by an 8-week resistance training and epicatechin supplementation in sarcopenic older adultsView study →

The load-bearing caveat: circulating epicatechin is conjugates (SREMs) and gut-microbial γ-valerolactones, not free aglycone ^{16Reference 16Ottaviani JI et al. · 2016The metabolome of 2-¹⁴C-epicatechin in humans — implications for the assessment of efficacy, safety and mechanisms of action of polyphenolic bioactivesView study →} — a likely reason the isolated aglycone underperforms a whole-cocoa matrix, and why inter-individual microbiome differences matter.

Pharmacokinetics

Unusually for a flavonoid, (−)-epicatechin is well absorbed. A definitive stable-isotope (¹⁴C) study in healthy men found ~82% of an oral dose was absorbed, with more than 20 metabolites and the gut microbiome as the dominant driver of overall metabolism ^{16Reference 16Ottaviani JI et al. · 2016The metabolome of 2-¹⁴C-epicatechin in humans — implications for the assessment of efficacy, safety and mechanisms of action of polyphenolic bioactivesView study →}; jejunal-perfusion work confirmed efficient uptake in the proximal small intestine with substantial first-pass conjugation and biliary/intestinal efflux ^{17Reference 17Actis-Goretta L et al. · 2013Intestinal absorption, metabolism, and excretion of (−)-epicatechin in healthy humans assessed by using an intestinal perfusion techniqueView study →}. But “absorbed” does not mean “free aglycone in blood”: what crosses the enterocyte is near-completely conjugated (glucuronidation, sulfation, O-methylation) to the structurally related epicatechin metabolites (SREMs) — chiefly epicatechin-3′-glucuronide, epicatechin-3′-sulfate and methylated sulfates ^{18Reference 18Natsume M et al. · 2003AnimalStructures of (−)-epicatechin glucuronide identified from plasma and urine after oral ingestion of (−)-epicatechin — differences between human and ratView study →}. Total SREM peaks are low-micromolar-to-high-nanomolar at ~1–2 h, cleared with a ~2–3 h half-life. The fraction reaching the colon is cleaved by microbiota to 5-(3′,4′-dihydroxyphenyl)-γ-valerolactones, which appear later, persist longer, and vary between people with their microbiome ^{16Reference 16Ottaviani JI et al. · 2016The metabolome of 2-¹⁴C-epicatechin in humans — implications for the assessment of efficacy, safety and mechanisms of action of polyphenolic bioactivesView study →}. This profile is specific to (−)-epicatechin — not EGCG (more poorly absorbed), not (+)-catechin (the epimer), and not the non-absorbed proanthocyanidin polymers.

Clinical trials

Epicatechin’s trial record is large but almost entirely cocoa-flavanol mixtures (endothelial function, BP, the COSMOS hard-outcome trial). Genuine pure-(−)-epicatechin efficacy RCTs are few — and their cardiovascular arms are null.

Cocoa-flavanol mixtures	Pure (−)-epicatechin	Hard-outcome	Cognition
Many RCTs + meta-analyses	Few (BP/FMD null; muscle mixed)	1 (COSMOS, primary null)	1 (COSMOS-Mind, null)

Last checked: July 2026.

Isolate vs. Plant Studies

Epicatechin is the textbook example of a molecule whose reputation rides on a mixture. The cardiovascular evidence is cocoa, not epicatechin: the FMD and blood-pressure benefits come from cocoa-flavanol extracts and dark chocolate, where epicatechin is only the presumed active among many flavanols and procyanidins ^{1,6Reference 1González-Sarrías A et al. · 2016Meta-analysisCocoa flavanol intake and biomarkers for cardiometabolic health — a systematic review and meta-analysisView study →Reference 6Sesso HD et al. · 2022RCTEffect of cocoa flavanol supplementation for the prevention of cardiovascular disease events — the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomised clinical trialView study →}. The purified monomer, tested alone, has failed to reproduce those vascular effects ^{4,5Reference 4Dower JI et al. · 2015RCTEffects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health — a randomised, double-blind, placebo-controlled crossover trialView study →Reference 52018RCTA nutritive dose of pure (−)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults — a randomised, placebo-controlled, double-blind crossover studyView study →}. Two mechanistic reasons are worth stating: the circulating species after any dose are conjugates and microbial γ-valerolactones rather than free epicatechin, and a whole-cocoa matrix may deliver co-factors (other flavanols, or effects on the microbiome) the isolate lacks ^{16Reference 16Ottaviani JI et al. · 2016The metabolome of 2-¹⁴C-epicatechin in humans — implications for the assessment of efficacy, safety and mechanisms of action of polyphenolic bioactivesView study →}. Within this database epicatechin is named across many herbs — cacao (its flagship source), tea, sarsaparilla, kratom and others — usually as an antioxidant co-constituent, and often bundled with (+)-catechin or as part of the proanthocyanidin fraction. A housekeeping note: it must not be conflated with (+)-catechin (separate page), EGCG (green-tea gallated catechin), or the proanthocyanidins (polymers) — and unlike (+)-catechin, epicatechin carries no cianidanol-style haemolysis history.

Prevalence in Nature

(−)-Epicatechin is one of the two dominant flavan-3-ol monomers in the plant kingdom (the 2,3-cis diastereomer of (+)-catechin) and a principal building block of proanthocyanidins ^{22,25Reference 22Neveu V et al. · 2010Phenol-Explorer — an online comprehensive database on polyphenol contents in foods ((−)-epicatechin, food values)View study →Reference 25Xie DY et al. · 2003Role of anthocyanidin reductase, encoded by BANYULS, in plant flavonoid biosynthesis (ANR → (−)-epicatechin)View study →}. Its richest common source by a wide margin is cocoa and dark chocolate — natural cocoa powder averages ~158 mg/100 g (range 63–330), dark chocolate ~70 mg/100 g, versus only ~15 mg/100 g in milk chocolate ^{22Reference 22Neveu V et al. · 2010Phenol-Explorer — an online comprehensive database on polyphenol contents in foods ((−)-epicatechin, food values)View study →}. It is also abundant in broad beans, apples (especially the skin and cider varieties), grapes and red wine, berries (blackberry, raspberry) and stone fruit, and it is a minor but consistent component of green and black tea (~7.9 and ~3.9 mg/100 mL respectively; black tea is lower because oxidative “fermentation” polymerises monomers into theaflavins), alongside red wine (~3.8 mg/100 mL) ^{22Reference 22Neveu V et al. · 2010Phenol-Explorer — an online comprehensive database on polyphenol contents in foods ((−)-epicatechin, food values)View study →}.

Processing destroys it — the critical caveat for cocoa. Raw beans are extremely rich (~30 mg/g defatted bean), but the chain to a chocolate bar is destructive at every step: fermentation and drying polymerise the monomer, roasting degrades it non-linearly (~8% loss under mild roasting rising to essentially complete destruction at 190–200 °C) ^{23Reference 23Fernández-Romero E et al. · 2020The kinetics of total phenolic content and monomeric flavan-3-ols during the roasting process of Criollo cocoaView study →}, and alkalisation (“Dutching”) collapses it further ^{24Reference 24Miller KB et al. · 2008Impact of alkalisation on the antioxidant and flavanol content of commercial cocoa powdersView study →}. This is why high-flavanol dark chocolate and minimally processed, non-alkalised cocoa are the headline sources while most confectionery is poor.

Biosynthetically, (−)-epicatechin comes from the anthocyanidin branch: leucoanthocyanidin → anthocyanidin → (via anthocyanidin reductase, ANR/BANYULS) → (−)-epicatechin (2,3-cis) — parallel to the leucoanthocyanidin-reductase (LAR) route that makes (+)-catechin (2,3-trans) ^{25Reference 25Xie DY et al. · 2003Role of anthocyanidin reductase, encoded by BANYULS, in plant flavonoid biosynthesis (ANR → (−)-epicatechin)View study →}. Both feed the proanthocyanidin polymers. There is essentially no non-plant source.

Discovery & Synthesis

(−)-Epicatechin shares the historical “catechin”/catechu naming lineage — originally from Acacia catechu / gambier (the same source that named its epimer and, in turn, the catechol functional group). Structurally it is a flavan-3-ol: a flavan with a 3-hydroxyl and a catechol B-ring (3,3′,4′,5,7-pentahydroxyflavan), and — crucially — no 4-oxo group and no C2–C3 double bond, so the C-ring is saturated and non-planar, with two stereocentres. The defining relationship is with catechin: (−)-epicatechin is the 2,3-cis epimer [(2R,3R)], (+)-catechin the 2,3-trans [(2R,3S)], and these two are by far the most abundant natural flavan-3-ol monomers. The cis geometry makes epicatechin prone to epimerise to catechin on heating — one reason cocoa and tea processing shift the isomer balance.

Commercially it is obtained by extraction from its rich sources (cocoa above all, plus tea, apples, grapes) and is specifically the epicatechin the cocoa-flavanol field studies; it also serves as the predominant extension unit of the procyanidins. Enantioselective total synthesis of flavan-3-ols exists (setting the two stereocentres by asymmetric dihydroxylation/epoxidation) and is used chiefly for isotopically-labelled standards — the ¹⁴C material behind the definitive PK study was made this way — but plant extraction remains the practical source ^{21Reference 21Yang Z et al. · 2019Asymmetric synthesis of chiral flavan-3-olsView study →}.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

As a dietary flavan-3-ol consumed for millennia in cocoa, tea, apples and grapes, (−)-epicatechin has very low intrinsic toxicity and is well tolerated in trials — cocoa-flavanol extracts delivering up to ~1,000 mg flavanols twice daily for up to three months were tolerated without adverse changes in blood pressure, platelets or lipids, and isolated-epicatechin dosing in small studies showed no serious safety signals. There is no established toxic dose for the monomer.

The best-established interaction is the flavan-3-ol class effect on non-heme iron: these catechol polyphenols chelate iron in the gut and dose-dependently reduce its absorption, so high-flavanol foods/supplements are best separated from iron-rich meals or iron supplements, particularly in iron deficiency ^{19Reference 19Hurrell RF et al. · 1999Inhibition of non-haem iron absorption in man by polyphenolic-containing beveragesView study →}. CYP/transporter signals exist in vitro but are weak-to-unestablished for epicatechin given how little free aglycone circulates — treat as theoretical. Two important non-interactions to state plainly: (−)-epicatechin does not carry the immune-haemolysis history of the (+)-catechin drug cianidanol (a different stereoisomer, at gram-scale drug doses) ^{20Reference 20Rotoli B et al. · 1985Immune-mediated acute intravascular haemolysis caused by cianidanol (Catergen) — the (+)-catechin drug, cited only to distinguish it from (−)-epicatechinView study →}, and the hepatotoxicity concern attached to concentrated green-tea/EGCG extracts is EGCG-driven and should not be generalised to dietary epicatechin.

Dosage

There is no established dose of isolated (−)-epicatechin, and the cardiovascular trials that “work” dose cocoa-flavanol mixtures — typically ~400–600 mg/day of flavan-3-ols from foods in the dietary-bioactive guideline (a food-pattern target, delivering on the order of 80 mg/day epicatechin), not a dose of the monomer ^{9Reference 9Crowe-White KM et al. · 2022Flavan-3-ols and cardiometabolic health — first ever dietary bioactive guidelineView study →}. Pure-epicatechin RCTs used 25–100 mg/day, and their cardiovascular arms were null ^{4,5Reference 4Dower JI et al. · 2015RCTEffects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health — a randomised, double-blind, placebo-controlled crossover trialView study →Reference 52018RCTA nutritive dose of pure (−)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults — a randomised, placebo-controlled, double-blind crossover studyView study →}.

These are descriptive research figures, not a recommendation — the class evidence is a food-pattern recommendation (cocoa, tea, apples, berries), and the isolated monomer has not been shown to reproduce the cardiovascular effects.

References